Acella Pharmaceuticals can’t seem to get its thyroid medicine right.
Acella recalled a whopping 35 commercial lots and three sample lots of NP Thyroid medicine, used to treat underactive thyroids, for sub-potency. Testing found these lots had less than 90% of the active ingredients liothyronine (T3) and/or levothyroxine (T4) as claimed on the bottle labels.
If this sounds familiar, Acella recalled certain lots of NP Thyroid for sub-potency in September 2020 and several lots of the drug in late May 2020 for “super potency.”
